Metrics as of 10/16/2026, 12:24 PM (Berlin time), refresh in progress.
Teva Pharmaceutical Industries Stock
Teva Pharmaceutical Industries Limited
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Israel
- CEO
- Richard D. Francis
- Employees
- 32,008
- Market cap
- $48.4 B
- IPO
- 16/02/1982
Teva Pharmaceutical Industries Limited is an international corporation in the Healthcare / Drug Manufacturers - Specialty & Generic sector, headquartered in Israel. Its portfolio covers a wide range of generics and biopharmaceuticals used for treating conditions such as central nervous system disorders like multiple…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Teva Pharmaceutical Industries stock: price history
1D
+1.0%
1W
+1.0%
1M
+7.8%
6M
+28.2%
YTD
+33.1%
1Y
+111.6%
2Y
+130.5%
5Y
+329.0%
10Y
-3.3%
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~89% stronger price swings than usual
Teva Pharmaceutical Industries stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
1 more assignment (Enabler/Second row) Pro-only.
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and distributes a broad portfolio of generics, biopharmaceuticals, and specialty medicines. Its business operations span various therapeutic areas including oncology, pain management, central nervous system disorders, and respiratory diseases. In addition to the sale of finished pharmaceutical products in various dosage forms, the portfolio includes active pharmaceutical ingredients (APIs). Revenue structure is primarily driven by product sales, while a smaller portion derives from services and licenses. The company operates in North America, Europe, and other international markets.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Moderate
- Moat
- Wide
- Moat type
- Switching costs
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Teva Pharmaceutical Industries
Analyst assessment of Teva Pharmaceutical Industries
PRICE TARGET LOW
US$44.00
CONSENSUS
US$47.33
MEDIAN
US$47.50
PRICE TARGET HIGH
US$50.00
0
STRONG BUY
21
BUY
21
HOLD
4
SELL
0
STRONG SELL
46
TOTAL · Buy
As of: 15/10/2026
Teva Pharmaceutical Industries stock metrics
P/E
65.38
P/B
6.19
EV/EBITDA
19.83
RETURN ON EQUITY
-7.4%
NET MARGIN
-13.9%
DEBT/EQUITY
2.18
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
95.1%
FLOAT SHARES
1,108,189,812
AVG. DAILY VOLUME (30D)
5,956,558
Insider transactions (SEC)
MIGNONE ROBERTO
Savage Brian
Savage Brian
Savage Brian
Savage Brian
Attention
Price since yesterday: +1.0%
Search (Google Trends)
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Teva Pharmaceutical Industries stock
What does Teva Pharmaceutical Industries do?
Teva Pharmaceutical Industries Limited is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in Israel.
The CEO is Richard D. Francis, the company employs around 32,008 people.
The IPO was on 16/02/1982; the stock trades on NYSE under the ticker TEVA.
What do analysts say about Teva Pharmaceutical Industries stock?
46 analysts rate the stock, the consensus is Buy (as of 15/10/2026).
The average price target is US$47.33, ranging from US$44.00 to US$50.00, with a median of US$47.50.
This is an external assessment, not a statement by Market Jury.
When does Teva Pharmaceutical Industries report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 89% stronger than usual.
Does Teva Pharmaceutical Industries pay a dividend?
Yes. The last dividend was US$0.09 per share, ex-date 27/11/2017, paid on 12/12/2017.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Teva Pharmaceutical Industries?
Comparable stocks include Merck, Takeda Pharmaceutical Company, Zoetis, Sandoz Group, Viatris, Lantheus Holdings, Amneal Pharmaceuticals and Indivior Pharmaceuticals.
How can I get Teva Pharmaceutical Industries stock analyzed?
Clicking "Analyze stock" lets five strategies assess Teva Pharmaceutical Industries against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.